Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.5.1.18 (
glutathione S-transferase
)
22,582
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We reported previously that protein associated with Myc (PAM) interacts with the C2 domain of type V adenylyl cyclase (
ACV
-C2) and that purified PAM is a potent inhibitor of Galphas-stimulated
ACV
activity (J Biol Chem 276:47583-47589, 2001). The present study was conducted to identify the region in PAM that inhibits
ACV
activity and to determine whether its binding with the
ACV
-C2 is necessary and sufficient to inhibit the enzyme. Coexpression of
ACV
and full-length PAM or its N-terminal third (PAM-N) in COS-7 cells inhibited isoproterenol-stimulated cAMP accumulation. Deletion of the RCC1 homology domains in PAM-N abolished its ability to inhibit isoproterenol-stimulated cAMP formation in cells. Purified
GST
fusion protein of the second RCC1 homology domain (RHD2) of PAM was sufficient to bind with
ACV
-C2 and inhibit Galphas-stimulated
ACV
activity. In addition, deletion of 11 amino acids in
GST
-RHD2 obliterated its ability to bind with and inhibit
ACV
. The C terminus of the RHD2 domain bound with
ACV
-C2 without inhibiting enzyme activity. Furthermore, substitution of His912 and His913 with alanine in the
GST
-RHD2 obliterated its ability to inhibit
ACV
without altering binding to
ACV
-C2. Likewise, H912/913A mutants of both PAM-N and full-length PAM did not inhibit cAMP formation in cells. Thus, the RHD2 domain of PAM is sufficient to inhibit Galphas-stimulated
ACV
activity and the binding of RHD2 to
ACV
-C2 is necessary but not sufficient for this inhibition. Moreover, His912 and His913 in PAM are critical for inhibiting
ACV
.
...
PMID:Histidine residues 912 and 913 in protein associated with Myc are necessary for the inhibition of adenylyl cyclase activity. 1547 80
Regulator of G Protein Signalling (RGS) proteins impede heterotrimeric G protein signalling. RGS2 decreases cAMP production and appears to interact with both adenylyl cyclase (AC) and its stimulatory G protein Gs. We showed previously that Green Fluorescent Protein-tagged RGS2 (GFP-RGS2) localizes to the nucleus in HEK 293 cells and is recruited to the plasma membrane when co-expressed with Gsalpha, or the Gs-coupled beta2-adrenergic receptor (beta2AR). Here, using confocal microscopy we show that co-expression of various AC isoforms (ACI, ACII,
ACV
, ACVI) also leads to GFP-RGS2 recruitment to the plasma membrane. Bioluminescence Resonance Energy Transfer (BRET) was also used to examine physical interactions between RGS2 and components of the Gs-signalling pathway. A BRET signal was detected between fusion constructs of RGS2-Renilla luciferase (energy donor) and Gsalpha-GFP (energy acceptor) co-expressed in HEK 293 cells. BRET was also observed between GFP-RGS2 and ACII or ACVI fused to Renilla luciferase. Additionally, RGS2 was found to interact with the beta2AR. Purified RGS2 selectively bound to the third intracellular loop of the beta2AR in
GST
pulldown assays, and a BRET signal was observed between GFP-RGS2 and beta2AR fused to Renilla luciferase when these two proteins were co-expressed together with either ACIV or ACVI. This interaction was below the limit of detection in the absence of co-expressed AC, suggesting that the effector enzyme stabilized or promoted binding between the receptor and the RGS protein inside the cell. Taken together, these results suggest the possibility that RGS2 might bind to a receptor-G protein-effector signalling complex to regulate Gs-dependent cAMP production.
...
PMID:RGS2 interacts with Gs and adenylyl cyclase in living cells. 1609 80